Avian Influenza Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (H5 Strain, H7 Strain, H9 Strain) By Application (Chicken, Duck & Goose, Others) Regional Forecast From 2025 To 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

AVIAN INFLUENZA VACCINES MARKET OVERVIEW

The global Avian Influenza Vaccines Market size stood at USD 1.24 billion in 2025, growing further to USD 2.65 billion by 2034 at an estimated CAGR of 8.83% from 2025 to 2034.

The United States Avian Influenza Vaccines Market size is projected at USD 0.39367 billion in 2025, the Europe Avian Influenza Vaccines Market size is projected at USD 0.35549 billion in 2025, and the China Avian Influenza Vaccines Market size is projected at USD 0.31249 billion in 2025.

Avian influenza, also known as bird flu, is a highly contagious viral disease that primarily affects birds but can also infect humans. In response to outbreaks of avian influenza, vaccines have been developed to protect birds and reduce the risk of human transmission. Avian influenza vaccines work by exposing birds to a weakened or inactivated form of the virus, triggering an immune response that prepares the bird's immune system to fight off a future infection. There are several different types of avian influenza vaccines, including inactivated vaccines, live attenuated vaccines, and recombinant vaccines. Inactivated vaccines contain dead virus particles, while live attenuated vaccines contain a weakened version of the virus. Recombinant vaccines use genetic engineering techniques to create a virus-like particle that triggers an immune response but cannot cause disease.

The market for avian influenza vaccines is growing due to several factors. One major factor is the increased awareness and concern about the potential for a global pandemic caused by the virus. The outbreaks of avian influenza in recent years have highlighted the need for effective vaccines to prevent the spread of the disease. In addition, the global demand for poultry products has been increasing, particularly in developing countries. This has led to an increase in the number of poultry farms and the density of poultry populations, creating a greater risk for the spread of avian influenza. As a result, governments and poultry producers are investing in preventative measures such as vaccination programs to protect their flocks and ensure a stable food supply. Moreover, the advancements in biotechnology and genetic engineering have enabled the development of more effective and efficient vaccines, driving the avian influenza vaccines market size. As research and development continue to improve, the demand for avian influenza vaccines is expected to increase in the coming years.

KEY FINDINGS

COVID-19 IMPACT

Production And Delivery Have Been Delayed As A Result Of Supply Chain Interruptions Brought On By The Pandemic

The COVID-19 pandemic has had a significant impact on the market for avian influenza vaccines. While the demand for the vaccine remains high, the supply chain disruptions caused by the pandemic have resulted in production and delivery delays. In addition, the diversion of resources and attention towards COVID-19 research and vaccine development has slowed down the progress of avian influenza vaccine development. Furthermore, the lockdowns and travel restrictions imposed to curb the spread of COVID-19 have disrupted global trade and transportation, affecting the availability and distribution of avian influenza vaccines. However, the pandemic has also highlighted the importance of vaccine research and development, leading to increased investments and collaborations in the field, which may accelerate the progress of avian influenza vaccine development in the long run. 

LATEST TRENDS

The Creation Of New, More Efficient Technology For Vaccine Production Is One Trend In The Market For Avian Influenza Vaccines

One trend in the market for avian influenza vaccines is the development of new, more effective technologies for vaccine production. Traditional egg-based methods of vaccine production have limitations in terms of scalability, speed, and cost-effectiveness. As a result, alternative technologies such as cell-based and recombinant DNA-based methods are gaining traction in the market. Leading players in the market, such as Zoetis, Boehringer Ingelheim, and Merck & Co., are investing in the development of these new technologies to enhance their vaccine offerings. For instance, Zoetis has launched a cell-based vaccine for avian influenza, which is produced using mammalian cells instead of eggs. Similarly, Boehringer Ingelheim has developed a recombinant vaccine that uses a virus-like particle to trigger an immune response. These new technologies are expected to improve vaccine efficacy, reduce production time and costs, and increase scalability, leading to wider availability of vaccines and better protection against avian influenza outbreaks.

• Regulatory approvals growing: As of May 2024, the EU reports 2 veterinary H5 vaccines authorised for chickens, reflecting faster regional authorisation pathways for poultry vaccines.

• Stockpile & preparedness purchases: Governments and agencies ordered millions of H5 doses for national stockpiles .

•   
•   
  

  Request a Free sample to learn more about this report

    

AVIAN INFLUENZA VACCINES MARKET SEGMENTATION

By Type

Depending on avian influenza vaccines market given are types: H5+H7 Avian Influenza Vaccines, H9 Avian Influenza Vaccines. The H5+H7 Avian Influenza Vaccines type will capture the maximum market share through 2033.

By Application

The market is divided into Chicken Avian Influenza Vaccines, Duck & Goose Avian Influenza Vaccines & Other based on application. The global avian influenza vaccines market players in cover segment like Chicken Avian Influenza Vaccines will dominate the market share during 2022-2033.

DRIVING FACTORS

The Rising Demand For Chicken Products In Emerging Nations Is One Reason Fueling The Market For Avian Influenza Vaccines

One driving factor behind the avian influenza vaccines market growth is the increasing demand for poultry products in developing countries. As economies grow and standards of living improve, there is a greater demand for animal protein sources, particularly poultry. However, this increased demand also leads to a higher risk of avian influenza outbreaks, which can have severe economic and public health consequences. To mitigate this risk, governments and poultry producers are investing in preventative measures such as vaccination programs. In addition, increasing consumer awareness of food safety and health concerns is also driving demand for avian influenza vaccines, as consumers demand assurance that their food supply is safe and free from disease. These factors are expected to continue to drive the growth of the avian influenza vaccine market in the coming years.

The Incidence And Severity Of Avian Influenza Outbreaks Growing Globally Is Another Factor Pushing The Market For Avian Influenza Vaccines

Another driving factor behind the market for avian influenza vaccines is the increasing prevalence and severity of avian influenza outbreaks worldwide. Over the past few years, there have been several high-profile outbreaks of avian influenza in various countries, resulting in significant economic losses and public health concerns. As a result, governments and poultry producers are increasingly investing in preventative measures, including vaccination programs, to control the spread of the virus and reduce the risk of transmission to humans. This has led to a significant increase in demand for avian influenza vaccines, particularly in regions with high poultry production and consumption. The continued threat of avian influenza outbreaks is expected to drive the avian influenza vaccines market growth in the foreseeable future.

• High livestock impact: FAO reported >131 million domestic poultry lost in 2022 due to HPAI, increasing pressure on policymakers to consider vaccination.

• Government funding & policy shifts: The U.S. allocated $1 billion (Feb 2025 plan) to combat avian influenza including investment in vaccines and vaccine innovation, which directly expands market opportunities for vaccine suppliers.

RESTRAINING FACTORS

The Regulatory Obstacles To Vaccine Development And Licensure Are One Restraint On The Market For Avian Influenza Vaccines

One restraining factor affecting the market for avian influenza vaccines is the regulatory barriers to vaccine development and approval. The regulatory approval process for new vaccines can be complex and time-consuming, requiring extensive pre-clinical and clinical testing to demonstrate safety and efficacy. This process can be particularly challenging for avian influenza vaccines, which require testing in live birds and may have limited commercial demand compared to other human vaccines. As a result, the development of new avian influenza vaccines may be delayed or halted due to regulatory hurdles, leading to a slower rate of innovation and limited availability of new and improved vaccines. Moreover, the high cost of vaccine development and production may also limit access to vaccines in low-income countries, where the risk of avian influenza outbreaks may be higher due to limited resources for disease control measures. These factors may restrain the avian influenza vaccines market growth and limit the global impact of avian influenza prevention efforts.

• Trade concerns: EU guidance explicitly notes farmed poultry are not routinely vaccinated in the EU and that vaccination can complicate trade, constraining broad market adoption in export-oriented regions.

• Strain mismatch risk: Scientific reviews note antigenic drift means vaccine strain mismatch risk is high — multiple reviews report dozens of H5 clades and changing circulating clades (e.g., clade 2.3.4.4b), requiring frequent updates and restraining single-product solutions.

•   
•   
  Request a Free sample to learn more about this report

    

AVIAN INFLUENZA VACCINES MARKET REGIONAL INSIGHTS

It Is Anticipated That Asia Pacific Would Continue To Dominate The Market In The Next Years

The Asia Pacific region is the leading region in the market for avian influenza vaccines, both in terms of market share and growth rate. The region is home to some of the world's largest poultry producers and consumers, including China, India, and Indonesia. These countries have experienced multiple avian influenza outbreaks in recent years, which has led to increased demand for avian influenza vaccines. Additionally, the growing demand for poultry products in the region is expected to drive the growth of avian influenza vaccines market share in the coming years. Moreover, the Asia Pacific region is also witnessing significant investment in vaccine research and development, with several local and multinational players launching new vaccines and expanding their production capacities. These factors are expected to continue to drive the growth of the market for avian influenza vaccines in the Asia Pacific region in the foreseeable future.

North America is the second-leading region in the market for avian influenza vaccines, following the Asia Pacific region. The region is home to some of the world's leading pharmaceutical and biotechnology companies, such as Zoetis and Merck & Co., which are major players in the avian influenza vaccine market. The North American market is driven by factors such as the increasing demand for high-quality poultry products and the threat of avian influenza outbreaks, which can have significant economic and public health consequences. Additionally, the region has a well-developed regulatory framework for vaccine development and approval, which has facilitated the launch of new vaccines and innovations in vaccine production. Moreover, the region has also witnessed significant investment in research and development of new avian influenza vaccines, with a focus on improving vaccine efficacy and reducing production costs. These factors are expected to continue to drive the growth of the market for avian influenza vaccines market share in North America in the coming years.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• Novartis AG: Novartis’ animal health business was the subject of acquisition activity — the Novartis Animal Health unit was agreed to be acquired for ~$5.4 billion (transaction announced 2014), linking Novartis legacy assets to later animal-health players.

• Eli Lilly and Company: Eli Lilly announced the acquisition of Novartis Animal Health (deal value ~$5.4 billion in 2014), building scale in animal health through that transaction.

List of Top Avian Influenza Vaccines Companies

• Novartis AG
• Eli Lilly and Company
• Ceva
• Merck & Co., Inc
• Mallinckrodt
• GlaxoSmithKline plc
• HIPRA
• YEBIO BIOENGINEERING CO., LTD OF QINGDAO
• F. Hoffmann-La Roche Ltd
• Medion
• AstraZeneca
• Elanco
• Virbac
• Phibro Animal Health Corporation
• Bayer AG
• Sanofi
• Bimeda, Inc
• Zoetis
• Vetoquinol
• Boehringer Ingelheim International GmbH
• Johnson & Johnson Private Limited

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.